Aerin Medical Inc.
“LASIK for the nose” to improve nasal breathing
This article was originally published in Start Up
Aerin Medical Inc.’s new procedure, called InFlux, could replace an invasive surgery with a 15-minute in-office procedure to help patients who complain of poor nasal breathing, and also serve people who simply want to breathe better.
You may also be interested in...
For innovators in the medical device industry, the otolaryngology or ENT (ear, nose, and throat) specialty offers just about everything that investors look for these days. Profiles of Aerin Medical, Spirox, Fiagon AG Medical, and ENTvantage Diagnostics.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.